Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

U.S. government reportedly passed on Pfizer offer to buy COVID-19 vaccine doses

By Brian Buntz | December 8, 2020

Pfizer BioNTechThe U.S. intends to order enough Pfizer’s COVID-19 vaccine for 50 million people, but the volume of COVID-19 vaccines the U.S. can procure could be limited until June 2021, according to the New York Times.

The cause of the potential shortfall stems from the Trump administration officials’ decision to pass on an offer from Pfizer (NYSE: PFE) to purchase an additional 500 million doses. As a result, Pfizer has commitments to other nations that could limit the volume it can provide the U.S.

At a recent rally in Georgia, President Trump touted his administration’s capacity to hasten mass vaccination. “Vaccines are on their way at a level that nobody ever thought possible,” he said. “It would’ve taken another administration five years. It took us seven months.”

Pfizer’s COVID-19 vaccine candidate, like many others intended to fight the pathogen, requires two doses.

The U.K. is preparing to administer the vaccine developed jointly by Pfizer and BioNTech (NSDQ:BNTX) as soon as next week. The U.K. is the first Western country to begin a mass-vaccination program.

The E.U. plans on purchasing 200 million doses of the Pfizer vaccine with an option to purchase an additional 100 million doses. Canada intends to purchase 76 million doses — enough to vaccinate the majority of its 38 million citizens. Administration of the vaccine could begin before the end of the month.

In the interim, President Trump is said to plan on signing an executive order to prioritize distributing vaccine doses domestically before sending them abroad.

Because Pfizer independently funded the R&D of the vaccine, an executive order intended to prioritize distribution of the vaccine in the U.S. would likely have little effect.

FDA will soon decide whether it will allow emergency use of the Pfizer vaccine.

The U.S. government has also purchased 100 million doses of Moderna’s COVID-19 vaccine, and has contracts with Johnson & Johnson, Novavax and AstraZeneca.

U.S. government officials told Fox News that the Trump administration has invested “at risk” in the COVID-19 vaccine candidates that are part of the Operation Warp Speed program.

“We guaranteed the purchase of 100 million doses of the Pfizer vaccine before they had initiated phase three clinical trials,” Health and Human Services Secretary Alex Azar told CNN. “They were not willing to give us a concrete date to commit to produce and deliver additional vaccines, so we secured a 500 million option for additional [doses].”


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: AstraZeneca plc, BioNTech, clinical trials, coronavirus, COVID-19 vaccine, FDA, Moderna, Pfizer
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50